Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacogen in HPV-Induced Anogenital and Head and Neck Cancer
NCT04252248Phase 1Terminated
- Sponsor
- Heidelberg University Hospital
- Start
- Oct 2019
- Primary completion
- Jun 2021
- Countries
- 1
01
Overview
Phase 1, open-label trial of decitabine in Ano-genital Carcinoma and head and neck cancer (HNC), sponsored by Heidelberg University Hospital. Primary endpoint: Dose Limiting Toxicities at 56 days. Started Oct 2019; status: terminated.
02
Drugs
decitabine
03
Conditions
Ano-genital Carcinomahead and neck cancer (HNC)
Beyond the preview
Go deeper on NCT04252248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04252248.